KLK3 and posterior cortical atrophy: Median pretreatment PSA for low-, intermediate-, and high-risk PCa was 5.4 ng/mL (IQR: 3.6 to 6.7 ng/mL), 6.6 ng/mL (IQR: 4.7 to 8.7 ng/mL), and 7.7 ng/mL (IQR: 5.5 to 10.1 ng/mL), respectively.